Klingman & Associates LLC Makes New Investment in Pfizer Inc. (NYSE:PFE)

Key Points

• Klingman & Associates LLC acquired a new stake in Pfizer Inc., purchasing 20,267 shares valued at approximately $514,000.
• Several large investors have significantly increased their holdings in Pfizer; for example, Pacer Advisors Inc. raised its stake by 856.8% in the first quarter.
• Pfizer reported a quarterly EPS of $0.78, surpassing the consensus estimate, along with a revenue increase of 10.3% year-over-year to $14.65 billion.

Klingman & Associates LLC acquired a new stake in Pfizer Inc. (NYSE:PFE - Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The fund acquired 20,267 shares of the biopharmaceutical company's stock, valued at approximately $514,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Brighton Jones LLC grew its holdings in Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock valued at $17,677,000 after buying an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC grew its holdings in shares of Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock worth $498,000 after purchasing an additional 2,087 shares in the last quarter. Mariner LLC grew its holdings in shares of Pfizer by 12.5% during the fourth quarter. Mariner LLC now owns 1,528,785 shares of the biopharmaceutical company's stock worth $40,558,000 after purchasing an additional 169,712 shares in the last quarter. CreativeOne Wealth LLC grew its holdings in shares of Pfizer by 15.2% during the fourth quarter. CreativeOne Wealth LLC now owns 135,564 shares of the biopharmaceutical company's stock worth $3,597,000 after purchasing an additional 17,891 shares in the last quarter. Finally, XTX Topco Ltd grew its holdings in shares of Pfizer by 69.9% during the fourth quarter. XTX Topco Ltd now owns 61,341 shares of the biopharmaceutical company's stock worth $1,627,000 after purchasing an additional 25,231 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Price Performance

PFE traded up $0.05 on Friday, hitting $25.16. 31,762,549 shares of the company's stock traded hands, compared to its average volume of 45,664,586. The company's 50 day simple moving average is $24.56 and its 200-day simple moving average is $24.46. The firm has a market cap of $143.05 billion, a price-to-earnings ratio of 13.38, a P/E/G ratio of 0.90 and a beta of 0.52. Pfizer Inc. has a one year low of $20.92 and a one year high of $30.43. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. The firm's quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the company earned $0.60 EPS. As a group, research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.8%. Pfizer's dividend payout ratio is currently 91.49%.

Analyst Upgrades and Downgrades

PFE has been the subject of several recent analyst reports. UBS Group boosted their price objective on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. The Goldman Sachs Group increased their price objective on Pfizer from $25.00 to $27.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Redburn Atlantic dropped their price objective on Pfizer from $29.00 to $27.00 and set a "neutral" rating for the company in a research note on Wednesday, April 30th. Wolfe Research increased their price objective on Pfizer from $22.00 to $23.00 and gave the company an "underperform" rating in a research note on Wednesday, April 30th. Finally, BMO Capital Markets dropped their price target on Pfizer from $36.00 to $30.00 in a research note on Thursday, April 17th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating, five have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer has a consensus rating of "Hold" and a consensus target price of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.